News
ZYME
6.73
-3.86%
-0.27
Zymeworks Names COO Neil Klompas as President
Zymeworks Names COO Neil Klompas as President
MT Newswires · 4d ago
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Zymeworks Q2 EPS $(0.97) Misses $(0.96) Estimate, Sales $5.44M Miss $6.07M Estimate
Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.96) by 1.04 percent. This is a 25.95 percent increase over losses of $(1.31) per share from the same
Benzinga · 5d ago
-- Earnings Flash (ZYME) ZYMEWORKS Reports Q2 Loss $-0.92
-- Earnings Flash (ZYME) ZYMEWORKS Reports Q2 Loss $-0.92
MT Newswires · 5d ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia & SEATTLE, August 01, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming inve...
Business Wire · 08/01 12:30
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/27 12:45
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
VANCOUVER, British Columbia & SEATTLE, July 25, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’s Phase 1 study of zanidatamab zovodotin (Z...
Business Wire · 07/25 12:30
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
VANCOUVER, British Columbia & SEATTLE, July 22, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule ...
Business Wire · 07/22 12:30
Zymeworks to Host Second Quarter Results Conference Call
VANCOUVER, British Columbia & SEATTLE, July 21, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results ...
Business Wire · 07/21 12:30
Zymeworks plans to become a Delaware corporation
Zymeworks (ZYME) has <a href="https://seekingalpha.com/pr/18867558-zymeworks-announces-plan-to-become-delaware-corp...
Seekingalpha · 07/15 12:38
BRIEF-Zymeworks Announces Plan To Become A Delaware Corporation
BRIEF-Zymeworks Announces Plan To Become A Delaware Corporation
Reuters · 07/15 12:07
Zymeworks Announces Plan To Become Delaware Corporation
Zymeworks Announces Plan to Become a Delaware Corporation Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain
Benzinga · 07/15 12:03
Zymeworks Announces Plan to Become a Delaware Corporation
VANCOUVER, British Columbia & SEATTLE, July 15, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced its intention to become a Delaware corp...
Business Wire · 07/15 12:00
Zymeworks Plans to Become a Delaware Corporation; Name, Brand, Ticker Symbol to Remain Unchanged
MT Newswires · 07/15 08:44
Zymeworks appoints new science chief
Zymeworks (NYSE:ZYME), a clinical-stage biotech focused on cancer therapeutics announced the appointment of biotech veteran Paul Moore as its new Chief Scientific Officer effective next month. Dr. Moore is expected
Seekingalpha · 06/27 13:11
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
VANCOUVER, British Columbia & SEATTLE, June 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team wi...
Business Wire · 06/27 12:30
Sector Update: Health Care Stocks Remain Lower in Late Friday Trading
MT Newswires · 06/10 15:47
BRIEF-Zymeworks Adopts Limited-Duration Shareholder Rights Plan
reuters.com · 06/10 13:58
Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay
reuters.com · 06/10 13:55
Zymeworks adopts shareholder rights plan after All Blue Falcons proposal
The board of clinical-stage biopharmaceutical company Zymeworks (NYSE:ZYME) adopted a limited-duration shareholder rights plan, intending to enable shareholders to realize the full value of their investment. The moves comes in
Seekingalpha · 06/10 13:33
More
Webull provides a variety of real-time ZYME stock news. You can receive the latest news about Zymeworks through multiple platforms. This information may help you make smarter investment decisions.
About ZYME
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.